These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 19120893)

  • 1. Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities.
    Kawai T; Yamagishi T; Yagi K; Kataoka M; Kawakami K; Sofuni A; Itoi T; Sakai Y; Moriyasu F; Osaka Y; Takagi Y; Aoki T; Rimbara E; Noguchi N; Sasatsu M
    J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S171-4. PubMed ID: 19120893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.
    Sugimoto M; Uotani T; Sahara S; Ichikawa H; Yamade M; Sugimoto K; Furuta T
    Helicobacter; 2014 Aug; 19(4):312-8. PubMed ID: 24690010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastric Juice-Based Real-Time PCR for Tailored
    Peng X; Song Z; He L; Lin S; Gong Y; Sun L; Zhao F; Gu Y; You Y; Zhou L; Zhang J
    Int J Med Sci; 2017; 14(6):595-601. PubMed ID: 28638276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance.
    Lee HJ; Kim JI; Cheung DY; Kim TH; Jun EJ; Oh JH; Chung WC; Kim BW; Kim SS; Park SH; Kim JK
    J Infect Dis; 2013 Oct; 208(7):1123-30. PubMed ID: 23801607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
    Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
    Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy.
    Prasertpetmanee S; Mahachai V; Vilaichone RK
    Helicobacter; 2013 Aug; 18(4):270-3. PubMed ID: 23356886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin.
    Oh JH; Dong MS; Choi MG; Yoo HW; Lee SB; Park YI; Chung IS
    J Gastroenterol Hepatol; 2009 Feb; 24(2):294-8. PubMed ID: 18823430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An assessment of the efficacy of first-line Helicobacter pylori-eradication therapy based on clarithromycin susceptibility.
    Miyaki A; Yamaguchi K; Ida A; Miyauchi T
    Minerva Gastroenterol Dietol; 2016 Sep; 62(3):234-9. PubMed ID: 27304198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study.
    Almeida N; Romãozinho JM; Donato MM; Luxo C; Cardoso O; Cipriano MA; Marinho C; Sofia C
    Helicobacter; 2014 Apr; 19(2):90-7. PubMed ID: 24506175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of detection of clarithromycin-resistant Helicobacter pylori from fecal specimens for young adults treated with eradication therapy.
    Osaki T; Mabe K; Zaman C; Yonezawa H; Okuda M; Amagai K; Fujieda S; Goto M; Shibata W; Kato M; Kamiya S
    Helicobacter; 2017 Oct; 22(5):. PubMed ID: 28544222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized treatment in the eradication therapy for Helicobacter pylori.
    Jinda S; Nakatani K; Nishioka J; Yasuda K; Soya Y; Hayashi A; Wada H; Nobori T
    Int J Mol Med; 2011 Feb; 27(2):255-61. PubMed ID: 21132257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
    Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
    Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori.
    Adachi T; Matsui S; Watanabe T; Okamoto K; Okamoto A; Kono M; Yamada M; Nagai T; Komeda Y; Minaga K; Kamata K; Yamao K; Takenaka M; Asakuma Y; Sakurai T; Nishida N; Kashida H; Kudo M
    Oncology; 2017; 93 Suppl 1():15-19. PubMed ID: 29258111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
    Furuta T; Shirai N; Xiao F; Takashita M; Sugimoto M; Kajimura M; Ohashi K; Ishizaki T
    Hepatogastroenterology; 2003; 50(54):2274-8. PubMed ID: 14696516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.
    Nishizawa T; Suzuki H; Nakagawa I; Iwasaki E; Masaoka T; Hibi T
    J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S167-70. PubMed ID: 19120892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial.
    Sue S; Ogushi M; Arima I; Kuwashima H; Nakao S; Naito M; Komatsu K; Kaneko H; Tamura T; Sasaki T; Kondo M; Shibata W; Maeda S
    Helicobacter; 2018 Apr; 23(2):e12456. PubMed ID: 29271026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis.
    Chang YW; Ko WJ; Oh CH; Park YM; Oh SJ; Moon JR; Cho JH; Kim JW; Jang JY
    Korean J Intern Med; 2019 Sep; 34(5):1022-1029. PubMed ID: 29898576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori.
    Furuta T; Sugimoto M; Shirai N; Matsushita F; Nakajima H; Kumagai J; Senoo K; Kodaira C; Nishino M; Yamade M; Ikuma M; Watanabe H; Umemura K; Ishizaki T; Hishida A
    Aliment Pharmacol Ther; 2007 Sep; 26(5):693-703. PubMed ID: 17697203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy.
    Furuta T; Shirai N; Xiao F; El-Omar EM; Rabkin CS; Sugimura H; Ishizaki T; Ohashi K
    Clin Gastroenterol Hepatol; 2004 Jan; 2(1):22-30. PubMed ID: 15017629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
    Branquinho D; Almeida N; Gregório C; Cabral JE; Casela A; Donato MM; Tomé L
    BMC Gastroenterol; 2017 Feb; 17(1):31. PubMed ID: 28202013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.